Immunoglobulins for Prophylaxis or Treatment of Infectious Diseases

Kyung-Hyo Kim

doi:10.5124/jkma.2008.51.12.1151

Journal List > J Korean Med Assoc > v.51(12) > 1041985

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Kim: Immunoglobulins for Prophylaxis or Treatment of Infectious Diseases

Pharmaotherapeutics

Journal of the Korean Medical Association

Journal of the Korean Medical Association 2008; 51(12): 1151-1157.

Published online: 31 December 2008

DOI: https://doi.org/10.5124/jkma.2008.51.12.1151

Immunoglobulins for Prophylaxis or Treatment of Infectious Diseases

Kyung-Hyo Kim, MD

Department of Pediatrics, Ewha Womans University College of Medicine, Korea. kaykim@ewha.ac.kr

Abstract

Administration of antibodies as a passive immunization is indicated for the replacement of deficiencies, prophylaxis or amelioration of infectious diseases for susceptible individuals and those at high risk for complications of infections. Antibodies can be administered either as human or animal plasma or serum, as pooled human immunoglobulin (IG) for intravenous or intramuscular use, as high-titer human IG from immunized or convalescing donors, or as monoclonal antibodies. Immunoglobulins are widely used for prevention of hepatitis A and measles and specific immunoglobulins are used for prevention of hepatitis B, tetanus, rabies, and varicella in susceptible people. A humanized murine monoclonal antibodies against respiratory syncytial virus have been licensed. This paper reviews the current use and recommendation of antibody products for the prevention and treatment of infectious diseases.

Keywords: Passive Immunization, Immunoglobulins, Infection, Prevention, Treatment

Figures and Tables

Table 1

Efficacy of antibody in the prevention and treatment of infectious diseases

Table 2

Guideline of tetanus prophylaxis in wound management

^*wounds contaminated with dirt, feces, soil, and saliva; puncture wounds; avulsions; wounds resulting from missiles, crushing, burns, and frostbite

^†Yes, if ≧ 10 years last tetanus-containing dose

^‡Yes, if ≧ 5 years last tetanus-containing dose

Table 3

Indications for post-exposure immunoprophylaxis of hepatitis B virus infection

Table 4

Indications for post-exposure immunoprophylaxis of varicella zoster virus infection

Table 5

Recommended intervals between immunoglobulin administration and MMR immunization

References

1. Pickering LK, Baker CJ, Long SS, McMillan JA, editors. American Academy of Pediatrics. Passive immunization. 2006 Red book: Report of the Committee on infectious diseases. 2006. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics;54–66.

2. American Academy of Pediatrics Committee on Infectious Diseases. Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics. 2003. 112:1442–1446.

3. Keller MA, Stiehm ER. Passive Immunity in Prevention and Treatment of Infectious Diseases. Clin Microbiol Rev. 2000. 13:602–614.

4. Pickering LK, Baker CJ, Long SS, McMillan JA, editors. American Academy of Pediatrics. Measles. Redbook: 2006 Report of the Committee on Infectious Diseases. 2006. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics;441–452.

5. Pickering LK, Baker CJ, Long SS, McMillan JA, editors. American Academy of Pediatrics. Varicella-zoster infections. Redbook: 2006 Report of the Committee on Infectious Diseases. 2006. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics;711–725.

TOOLS

Similar articles